| Symbol | KLRS |
|---|---|
| Name | KALARIS THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 1100 WINTER STREET,SUITE 500, WALTHAM, Massachusetts, 02451, United States |
| Telephone | +1 212 915 2577 |
| Fax | — |
| — | |
| Website | https://www.kalaristx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001754068 |
| Description | Kalaris was founded by experienced leaders in ophthalmology drug development and commercialization to address a major unmet need in the treatment of retinal diseases.Existing therapies for retinal neovascular / exudative diseases have made great strides in preserving or improving vision, but they require frequent clinic visits over many years that place a significant burden on patients and caregivers. This onerous visit regimen often leads to missed or delayed injections and suboptimal patient outcomes. Additional info from NASDAQ: |
Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling
Read moreJovan-Embiricos Morana 🟢 acquired 9.0K shares (1 derivative) of Kalaris Therapeutics, Inc. (KLRS) at $4.72 Transaction Date: Jun 03, 2026 | Filing ID: 257564
Read moreFerrara Napoleone 🟢 acquired 9.0K shares (1 derivative) of Kalaris Therapeutics, Inc. (KLRS) at $4.72 Transaction Date: Jun 03, 2026 | Filing ID: 257556
Read moreHallal David 🟢 acquired 9.0K shares (1 derivative) of Kalaris Therapeutics, Inc. (KLRS) at $4.72 Transaction Date: Jun 03, 2026 | Filing ID: 257494
Read moreAKKARAJU SRINIVAS 🟢 acquired 9.0K shares (1 derivative) of Kalaris Therapeutics, Inc. (KLRS) at $4.72 Transaction Date: Jun 03, 2026 | Filing ID: 257471
Read moreDybbs Michael 🟢 acquired 9.0K shares (1 derivative) of Kalaris Therapeutics, Inc. (KLRS) at $4.72 Transaction Date: Jun 03, 2026 | Filing ID: 257465
Read moreADAMIS ANTHONY P 🟢 acquired 9.0K shares (1 derivative) of Kalaris Therapeutics, Inc. (KLRS) at $4.72 Transaction Date: Jun 03, 2026 | Filing ID: 257462
Read morePATTERSON LEONE D 🟢 acquired 9.0K shares (1 derivative) of Kalaris Therapeutics, Inc. (KLRS) at $4.72 Transaction Date: Jun 03, 2026 | Filing ID: 257445
Read more(99% Neutral) KALARIS THERAPEUTICS, INC. (KLRS) Announces Regulatory Update
Read more